A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Trial Details

NCT ID

NCT06564038

Phase

PHASE1 / PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

Surovatamig
Prednisone (or equivalent)
Rituximab
Cyclophosphamide
Vincristine
Doxorubicin

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
Hackensack, New Jersey, United States|40.88593,-74.04347
New York, New York, United States|40.71427,-74.00597
Charlotte, North Carolina, United States|35.22709,-80.84313
Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

Master Inclusion Criteria applicable to all substudies:
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Contraception use during treatment and at least 90 days after final dose.
Confirmed CD19 expression if prior anti-CD19 therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →